1. Home
  2. MMA vs INTS Comparison

MMA vs INTS Comparison

Compare MMA & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alta Global Group Limited

MMA

Alta Global Group Limited

HOLD

Current Price

$0.51

Market Cap

13.9M

Sector

N/A

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$4.78

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMA
INTS
Founded
2013
2012
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9M
12.9M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
MMA
INTS
Price
$0.51
$4.78
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$38.00
AVG Volume (30 Days)
761.8K
64.3K
Earning Date
05-20-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.19
52 Week High
$2.00
$8.06

Technical Indicators

Market Signals
Indicator
MMA
INTS
Relative Strength Index (RSI) 47.46 66.87
Support Level $0.35 $4.50
Resistance Level $0.58 $8.06
Average True Range (ATR) 0.04 0.23
MACD 0.00 0.13
Stochastic Oscillator 53.28 83.34

Price Performance

Historical Comparison
MMA
INTS

About MMA Alta Global Group Limited

MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: